Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 plus sintilimab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
CTR20210080Phase 3Completed
- Sponsor
- InnoCare Pharma
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of IBI310, sintilimab, sorafenib in hepatocellular carcinoma (HCC), sponsored by InnoCare Pharma. Started Feb 2021; status: completed.
02
Drugs
IBI310sintilimabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20210080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210080.